The Metastatic Ovarian Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Ovarian Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued products.
GlobalData tracks 119 drugs in development for Metastatic Ovarian Cancer by 107 companies/universities/institutes. The top development phase for Metastatic Ovarian Cancer is phase i with 53 drugs in that stage. The Metastatic Ovarian Cancer pipeline has 114 drugs in development by companies and five by universities/ institutes. Some of the companies in the Metastatic Ovarian Cancer pipeline products market are: TScan Therapeutics, Lyvgen Biopharma and Alphamab Oncology.
The key targets in the Metastatic Ovarian Cancer pipeline products market include Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1).
The key mechanisms of action in the Metastatic Ovarian Cancer pipeline product include Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Inhibitor with four drugs in Phase II. The Metastatic Ovarian Cancer pipeline products include 13 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Metastatic Ovarian Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Ovarian Cancer overview
Metastatic ovarian cancer results from the spread of ovarian cancer cells beyond the ovaries, commonly reaching the peritoneum, liver, lungs, and lymph nodes. Symptoms like abdominal pain, weight loss, and digestive changes may manifest. Diagnosis involves imaging, blood tests, and surgical biopsy. Staging determines treatment strategies, typically involving surgery and chemotherapy. Prognosis varies, influenced by factors such as metastatic extent and treatment response. Ongoing management includes regular monitoring and potential participation in clinical trials for innovative therapies. Early detection remains crucial for optimizing outcomes in the challenging context of metastatic ovarian cancer.
For a complete picture of Metastatic Ovarian Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
